Magnetic Resonance Imaging of Delayed Enhancement in Hypertrophic Cardiomyopathy: Relationship with Left Ventricular Perfusion and Contractile Function

Purpose: The aim of the study was to analyze the relationship between myocardial delayed enhancement, first-pass perfusion, and contractile function in hypertrophic cardiomyopathy (HCM) patients, using MR. Methods: Fifty-three patients diagnosed with HCM were prospectively examined using a 1.5-T MR unit. Multiphase gradient-echo sequences were performed to study global left ventricular function, wall thickness, and left ventricular mass. Myocardial tissue tagging was conducted to evaluate contractile function. T1-weighted inversion-recovery sequences were obtained at rest to study myocardial contrast enhancement at first pass and delayed enhancement 10 minutes later. Results: Delayed enhancement found in 30 patients (56.6%) was most commonly seen in hypertrophic segments. Nine patients exhibited delayed enhancement in segments with normal wall thickness (<15 mm). Sixteen patients (30.1%) showed first-pass perfusion defects at rest, which were associated with significantly lower stroke volume (P < 0.05) and lower cardiac output (P < 0.01). The hypokinetic segments found in 16 patients (30.1%) were significantly thicker at end diastole (P < 0.01). Delayed enhancement correlated positively with perfusion defects (r = 0.5, P < 0.01) and hypokinetic segments (r = 0.3, P < 0.05). Conclusion: Delayed myocardial enhancement is most commonly found in hypertrophic segments but also can be seen in segments with normal wall thickness. Perfusion defects at rest and impaired contractile function are related abnormalities with delayed myocardial enhancement. Further studies are necessary to assess the role of myocardial tagging, first-pass perfusion, and delayed enhancement in risk stratification for patients with HCM.Abbreviations: MCH = hypertrophic cardiomyopathy, FOV = field of view

[1]  P. Dimitrow,et al.  Delayed contrast enhancement of MRI in hypertrophic cardiomyopathy. , 2004, Magnetic Resonance Imaging.

[2]  Y. Amano,et al.  Delayed hyper‐enhancement of myocardium in hypertrophic cardiomyopathy with asymmetrical septal hypertrophy: Comparison with global and regional cardiac MR imaging appearances , 2004, Journal of magnetic resonance imaging : JMRI.

[3]  Robert R Edelman,et al.  Contrast-enhanced MR imaging of the heart: overview of the literature. , 2004, Radiology.

[4]  J. Willmann,et al.  Coronary artery bypass grafts: ECG-gated multi-detector row CT angiography--influence of image reconstruction interval on graft visibility. , 2004, Radiology.

[5]  Dudley J Pennell,et al.  The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. , 2004, Journal of the American College of Cardiology.

[6]  I. Olivotto,et al.  Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. , 2003, The New England journal of medicine.

[7]  P. Austin,et al.  Waiting times, revascularization modality, and outcomes after acute myocardial infarction at hospitals with and without on-site revascularization facilities in Canada. , 2003, Journal of the American College of Cardiology.

[8]  D. Pennell,et al.  Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. , 2003, Journal of the American College of Cardiology.

[9]  Jan Bogaert,et al.  Late Myocardial Enhancement in Hypertrophic Cardiomyopathy with Contrast-Enhanced MR Imaging , 2003 .

[10]  S. Dymarkowski,et al.  Original report. Late myocardial enhancement in hypertrophic cardiomyopathy with contrast-enhanced MR imaging. , 2003, AJR. American journal of roentgenology.

[11]  Esko Vanninen,et al.  First-pass MR imaging in the assessment of perfusion impairment in patients with hypertrophic cardiomyopathy and the Asp175Asn mutation of the alpha-tropomyosin gene. , 2003, Radiology.

[12]  Heiko Mahrholdt,et al.  Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. , 2002, Journal of the American College of Cardiology.

[13]  R. Kim,et al.  Reproducibility of Chronic Infarct Size Measurement by Contrast-Enhanced Magnetic Resonance Imaging , 2002, Circulation.

[14]  D. Pennell,et al.  Breath-hold FLASH and FISP cardiovascular MR imaging: left ventricular volume differences and reproducibility. , 2002, Radiology.

[15]  M. Cerqueira,et al.  Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association , 2002, The international journal of cardiovascular imaging.

[16]  M. Cerqueira,et al.  Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. , 2002, Circulation.

[17]  G Thiene,et al.  Hypertrophic cardiomyopathy and sudden death in the young: pathologic evidence of myocardial ischemia. , 2000, Human pathology.

[18]  B. Maron,et al.  Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. , 2000, The New England journal of medicine.

[19]  A. Marian Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy , 2000, The Lancet.

[20]  William J. McKenna,et al.  Identificación y tratamiento de los pacientes con miocardiopatía hipertrófica y riesgo de muerte súbita , 2000 .

[21]  W. Roberts,et al.  Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. , 2000, Journal of the American College of Cardiology.

[22]  N. Reichek MRI myocardial tagging , 1999, Journal of magnetic resonance imaging : JMRI.

[23]  R. Soler,et al.  Left ventricular mass in hypertrophic cardiomyopathy: assessment by three-dimensional and geometric MR methods. , 1999, Journal of computer assisted tomography.

[24]  C. Higgins,et al.  Hypertrophic cardiomyopathy: MR measurement of coronary blood flow and vasodilator flow reserve in patients and healthy subjects. , 1999, Radiology.

[25]  C. M. Lowe,et al.  Dipyridamole stress thallium-201 perfusion abnormalities in patients with hypertrophic cardiomyopathy. Relationship to clinical presentation and outcome. , 1998, European heart journal.

[26]  P. Dardas,et al.  Transthoracic Doppler echocardiographic analysis of phasic coronary blood flow velocity in hypertrophic cardiomyopathy. , 1997, Heart.

[27]  T. Ino,et al.  Apoptosis as a possible cause of wall thinning in end-stage hypertrophic cardiomyopathy. , 1997, The American journal of cardiology.

[28]  M. Burch,et al.  Hypertrophic cardiomyopathy. , 1994, Archives of disease in childhood.

[29]  F. Sardanelli,et al.  MRI in Hypertrophic Cardiomyopathy: A Morphofunctional Study , 1993, Journal of computer assisted tomography.

[30]  V. Dilsizian,et al.  Regional systolic function, myocardial blood flow and glucose uptake at rest in hypertrophic cardiomyopathy. , 1993, The American journal of cardiology.

[31]  W. Roberts,et al.  Myocardial disarray at junction of ventricular septum and left and right ventricular free walls in hypertrophic cardiomyopathy. , 1992, The American journal of cardiology.

[32]  A. L'Abbate,et al.  Coronary vasodilation is impaired in both hypertrophied and nonhypertrophied myocardium of patients with hypertrophic cardiomyopathy: a study with nitrogen-13 ammonia and positron emission tomography. , 1991, Journal of the American College of Cardiology.

[33]  W. Roberts,et al.  Intramural ("small vessel") coronary artery disease in hypertrophic cardiomyopathy. , 1986, Journal of the American College of Cardiology.

[34]  Z. Krajcer,et al.  Coronary artery disease in hypertrophic cardiomyopathy. , 1985, The American journal of cardiology.